GlobeNewswire·Nov 10, 2026, 6:02 PM ET

Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO

Immutep Limited released preliminary long-term survival data from the EFTISARC-NEO Phase II trial at CTOS 2026.
The trial evaluated eftilagimod alfa (efti) plus KEYTRUDA (pembrolizumab) & radiotherapy as neoadjuvant treatment for resectable soft tissue sarcoma (STS).
In 38 evaluable patients with a median follow-up of 19.1 months, 12-month disease-free survival (DFS), local recurrence-free survival (LRFS), & distant metastasis-free survival (DMFS) rates were 81.1%, 94.1%, & 86.2%, respectively.
No DFS differences were observed across tumour grade, stage, or histological subtype.
Investigators noted that high tumour-infiltrating lymphocyte (TIL) infiltration & tumour hyalinisation/fibrosis may correlate with better DFS, though longer follow-up is required.
The trial met its primary endpoint in October 2025 with median tumour hyalinisation/fibrosis of 51.5%, exceeding the 35% target.
Health-related quality of life data showed no significant deterioration during treatment & a statistically significant improvement post-surgery.
The U.S. FDA granted Orphan Drug Designation to efti for STS treatment in April 2026.
Further analyses will be presented in a poster discussion session on 19 November 2026 at the CTOS Annual Meeting in Seoul, South Korea.
Follow-up for DFS & overall survival remains ongoing.